Novelties in the field of autoimmunity – 1st Saint Petersburg congress of autoimmunity, the bridge between east and west

Dahan, Shani; Segal‬‏, Yahel; Watad, Abdulla; Azrielant, Shir; Shemer, Asaf; Maymon, Dror; Stroev, Yuri I.; Sobolevskaya, Polina A.; Корнева, Е. А.; Blank, Miri; Gilburd, Boris; Shovman, Ora; Amital, Howard; Ehrenfeld, Michael; Tanay, Amir; Kivity, Shay; Pras, Elon; Chapman, Justin; Damoiseaux, Jan; Cervera, Ricard; Putterman, Chaim; Shapiro, Iziaslav; Mouthon, Luc; Perricone, Roberto; Bizzaro, Nicola; Koren, Omry; Riemekasten, Gabriela; Chereshnev, V. А.; Мазуров, В. И.; Goloviznin, Mark; Gurevich, V. S.; Чурилов, Леонид Павлович; Shoenfeld, Yehuda

doi:10.1016/j.autrev.2017.10.001

Cited by 17 publications

(5 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in the EUROAPS registry we only found 14-16% of patients with low complement values (less than expected), possibly due to the lack of information in some patients. In the same line, we have observed a high frequency of vitamin D deficit (21.4% of patients), suggesting an involvement in the OAPS generation [56,57]. To conclude, we would like to highlight the good results achieved in the comparative between different treatment schedules (Table 7).…”

Section: Tablesupporting

confidence: 59%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

Self Cite

126

View full text Add to dashboard Cite

show abstract

Section: Tablesupporting

confidence: 59%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

Self Cite

126

View full text Add to dashboard Cite

show abstract

“…Additionally, decreased regulatory T cells have been noted in SIgAD individuals with autoimmunity [ 37 , 83 ]. It appears that both the interplay of humoral and cellular immunity contribute to the development of autoimmunity in patients with SIgAD [ [84] , [85] ].…”

Section: Clinical Manifestations and Managementmentioning

confidence: 99%

The clinical implications of selective IgA deficiency

Swain

Selmi

Gershwin

et al. 2019

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

Selective IgA deficiency (SIgAD) is the most common primary immunodeficiency but does not always result in clinical disease. This may in part be due to the definition based on serum IgA, while most IgA is secreted at mucosal surfaces, not amenable to measurement. Clinical complications include increased risk of sinopulmonary infections with bacteria and viruses, gastrointestinal infections with a predilection for Giardia lamblia , a myriad of autoimmune diseases including systemic lupus erythematosus, hyper- and hypo-thyroidism, Type 1 diabetes, celiac disease, and rarely, malignancy. SIgAD must be differentiated from IgA deficiency that may be seen with IgG2 or IgG4 deficiency, specific antibody deficiency, or as an early manifestation prior to a diagnosis of common variable immunodeficiency. Secondary IgA deficiency is increasingly recognized and may be due to medications such as anti-epileptics, or antibiotics with disruption of the microbiome which can influence IgA levels, infections or malignancies. Patients with SIgAD should be monitored at regular intervals and educated to be aware of particular complications. There is a rare chance of development of anti-IgA IgE antibodies in patients with complete deficiency, which can result in anaphylaxis if blood products with IgA are administered. Prophylactic antibiotics may be indicated in some cases, and very rarely, supplemental IgG infusions.

show abstract

“…Other proposed interventions include prebiotics and probiotics, both of which may shift the balance of the microbiotal composition towards protective microbes, which harbor anti-inflammatory properties [ 174 , 175 ]. Some prebiotics have demonstrated ability to regulate cytokine levels [ 100 ], such as whole grains, which demonstrated ability to decrease IL-6 levels [ 176 ] and butylated high amylose maize starch, which has shown ability to increase levels of IL-10 in human cohorts [ 177 ]. Even fecal transplantation is contemplated from healthy donors to critically ill COVID-19 patients, as ways to promote a healthier immune response in these patients, although the presence of SARS-CoV-2 in the feces must be ruled out [ 178 ].…”

Section: The Microbiome and Covid-19 Therapymentioning

confidence: 99%

Autoimmunity and COVID-19 – The microbiotal connection

Katz-Agranov

Zandman‐Goddard

2021

Autoimmunity Reviews

View full text Add to dashboard Cite

Background and aims The novel SARS-CoV-2 has been rattling the world since its outbreak in December 2019, leading to the COVID-19 pandemic. The learning curve of this new virus has been steep, with a global scientific community desperate to learn how the virus is transmitted, how it replicates, what cause such a wide spectrum of disease manifestations, causing none or few symptoms in some. Others are burdened by an intense immune response that resembles the cytokine storm syndrome (CSS), which leads to severe disease manifestations, often complicated by fatal acute respiratory distress syndrome and death. Research efforts have been focusing on finding effective cures and vaccinations for this virus. The presence of SARS-CoV-2 in the gastrointestinal (GI) tract, represented by several GI manifestations, has led to its investigation as a target for the virus and as an indicator of disease severity. The response of the microbiome (which is heavily linked to immunity) to the novel SARS-CoV-2 virus, and its role in igniting the exaggerated immune response has therefore become a focus of interest. The objective of our study was to gather the data connecting between the microbiome, the GI tract and COVID-19 and to investigate whether these reported alterations in the gut microbiome bear any resemblance to those seen in lupus, the prototypical autoimmune disease. Confirming such changes may become the steppingstone to potential therapies that may prevent transmission, progression and immune related manifestations of COVID-19, via manipulation of the gut microbiota. Methods We performed an extensive literature review, utilizing the Pubmed search engine and Google Scholar for studies evaluating the microbiome in COVID-19 patients and compared results with studies evaluating the microbiome in lupus. We searched for the terms: microbiome, dysbiosis, COVID-19, SARS-CoV-2, gastrointestinal as well as lupus and autoimmune. While there were hundreds of articles which referred to gastrointestinal manifestations in COVID-19, to date only 4 studies investigated the gastrointestinal microbiome in this setting. We compared the similarities between microbiome of COVID-19 patients and lupus patients. Results We found that there are several similar processes of immune dysregulation in patients with COVID-19 and in those with lupus, with several other alterations seen in other pathological states. Some of these similarities include loss of microbiota biodiversity, increased representation of pathobionts, which are microbes associated with inflammation and disease (i.e Proteobacteria) and a relative decrease of symbionts, which are protective microbes, associated with anti-inflammatory properties (i.e Lactobacillus). Compromise to the intestinal barrier has also been reported in both. Conclusions We conclude that the gastrointestinal tract contributes to the disease manifestations in COVID-19. Whether gastrointestinal dysb...

show abstract

Novelties in the field of autoimmunity – 1st Saint Petersburg congress of autoimmunity, the bridge between east and west

Cited by 17 publications

References 108 publications

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

The clinical implications of selective IgA deficiency

Autoimmunity and COVID-19 – The microbiotal connection

Contact Info

Product

Resources

About